for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Chiasma Inc

CHMA.OQ

Latest Trade

5.48USD

Change

-0.01(-0.18%)

Volume

69,672

Today's Range

5.22

 - 

5.51

52 Week Range

2.12

 - 

9.23

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
5.49
Open
5.50
Volume
69,672
3M AVG Volume
5.59
Today's High
5.51
Today's Low
5.22
52 Week High
9.23
52 Week Low
2.12
Shares Out (MIL)
42.02
Market Cap (MIL)
230.67
Forward P/E
-5.34
Dividend (Yield %)
--

Next Event

Q4 2019 Chiasma Inc Earnings Release

Latest Developments

More

Chiasma Posts Q3 Loss Per Share Of $0.20

Chiasma Files For Mixed Shelf Of Up To $200 Million

Chiasma Reports Q2 Loss Per Share $0.25

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Chiasma Inc

Chiasma, Inc. is a biopharmaceutical company. The Company is engaged in developing and commercializing oral forms of therapies that are available only by injection. Using its Transient Permeability Enhancer (TPE) technology platform, the Company is developing oral therapies. The Company has completed a Phase III clinical trial of its TPE platform-based product candidate, oral octreotide capsules (trade named as MYCAPSSA) for the treatment of acromegaly, a condition that results in the body's production of excess growth hormone. Octreotide is an analog of somatostatin, a natural inhibitor of growth hormone secretion. The Company is developing octreotide capsules as a liquid-filled solid gelatin capsule formulation, which is intended to be taken over twice a day. The Company's TPE technology enhances the absorption through the intestinal wall of drugs. The Company also focuses on developing CH2 for Orphan indication.

Industry

Biotechnology & Drugs

Contact Info

460 Totten Pond Rd Ste 530

+1.617.9285300

http://www.chiasmapharma.com/

Executive Leadership

David M. Stack

Independent Chairman of the Board

Mark J. Fitzpatrick

President, Principal Financial Officer

Raj Kannan

Chief Executive Officer, Director

William Ludlam

Senior Vice President - Clinical Development and Medical Affairs

Drew Enamait

Principal Accounting Officer, Vice President - Finance and Administration, Corporate Controller

Key Stats

2.00 mean rating - 5 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2016

0.0K

2017

0.0K

2018

0.0K

2019(E)

0.0K
EPS (USD)

2016

-2.510

2017

-1.100

2018

-1.280

2019(E)

-1.028
Price To Earnings (TTM)
--
Price To Sales (TTM)
--
Price To Book (MRQ)
2.38
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
1.39
LT Debt To Equity (MRQ)
0.00
Return on Investment (TTM)
-46.40
Return on Equity (TTM)
-41.01

Latest News

Latest News

BRIEF-Chiasma Announces FDA Agreement To Redefine Certain Secondary Endpoints In Phase 3 Clinical Trial

* CHIASMA ANNOUNCES FDA AGREEMENT TO REDEFINE CERTAIN SECONDARY ENDPOINTS IN CHIASMA OPTIMAL PHASE 3 CLINICAL TRIAL

BRIEF-Chiasma Inc Files For Mixed Shelf Of Up To $100 Million

* CHIASMA INC FILES FOR MIXED SHELF OF UP TO $100 MILLION – SEC FILING Source text: (https://bit.ly/2DLHB1V) Further company coverage:

BRIEF-Chiasma Q4 Loss Per Share $0.25

* EXPECTS TO HAVE A CASH AND INVESTMENT BALANCE OF AT LEAST $35 MILLION AT END OF 2018 Source text for Eikon: Further company coverage:

BRIEF-Chiasma Announces Expected Year-End 2017 Cash And Investments Balance Of About $67 Mln

* CHIASMA INC - ANNOUNCES EXPECTED YEAR-END 2017 CASH AND INVESTMENTS BALANCE OF APPROXIMATELY $67 MILLION

BRIEF-Chiasma Q3 loss per share $0.28

* Chiasma Inc - cash, cash equivalents & marketable securities as of Sept 30, 2017 were $73.2 million, compared with $93.0 million as of December 31, 2016 Source text for Eikon: Further company coverage:

BRIEF-Chiasma announces first patient is randomized in phase 3 trial of Octreotide capsules in patients with acromegaly

* Chiasma announces first patient is randomized in phase 3 chiasma optimal clinical trial of Octreotide capsules in patients with acromegaly

BRIEF-Chiasma reached deal with FDA on late-stage trial of its acromegaly drug

* Chiasma reaches agreement with FDA under special protocol assessment for a new phase 3 clinical trial of octreotide capsules in acromegaly

BRIEF-Chiasma reports Q1 loss per share $0.29

* Chiasma Inc - following receipt of crl for octreotide capsules NDA, company participated in an end of review meeting with FDA

BRIEF-Chiasma Q4 loss per share $0.32

* Chiasma Inc - for quarter ended december 31, 2016, net loss attributable to common stockholders was $7.9 million, or $0.32 per basic share. Source text for Eikon: Further company coverage:

BRIEF-Chiasma provides year-end corporate update and preliminary outlook for 2017

* Chiasma provides year-end corporate update and preliminary outlook for 2017

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up